Recent epidemiological studies have established an association between the common
consumption of coffee or other caffeinated beverages and a reduced risk of developing …

Considerable epidemiological and laboratory data have suggested that caffeine, a
nonselective adenosine receptor antagonist, may protect against the underlying …

The adenosine A2A receptor has recently emerged as a leading non-dopaminergic
therapeutic target for Parkinson's disease, largely due to the restricted distribution of the …

A remarkable convergence of epidemiologic and laboratory data has raised the possibility
that caffeine reduces the risk of developing Parkinson's disease (PD) by preventing the …

Epidemiological studies have raised the possibility of caffeine serving as a neuroprotective
agent in Parkinson's disease (PD). This possibility has gained support from findings that …

The risk of Parkinson's disease (PD) is associated with a lower intake of caffeine, a non-
selective adenosine A2A antagonist. In agreement, genetic or pharmacological inactivation …

Adenosine A2A receptors are abundant in the caudate‐putamen and involved in the motor
control in several species. In MPTP‐treated monkeys, A2A receptor‐blockade with an …

Parkinson's disease (PD) is the second most common neurodegenerative disorder affecting
1 to 3% of individuals over the age of 65 years. While effective therapy exists for treating the …

We investigated the effect of chronic daily caffeine treatment on caffeine's neuroprotection
against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced dopaminergic …

Large prospective epidemiologic studies have linked the consumption of coffee and other
caffeinated beverages to a reduced risk of subsequently developing PD. Caffeine as well as …